Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach

Zohar Habot-Wilner, Glenn Noronha, Charles C. Wykoff

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the anatomy and clearance pharmacokinetics of the eye. Systemic and several local administration options [topical, periocular, intravitreal (IVT) and subretinal] are in clinical use, each with a unique benefit to risk profile shaped by factors including the administered agent, frequency of dosing, achievable pharmaceutical concentrations within posterior segment structures versus elsewhere in the eye or the body, invasiveness of the procedure and the inherent challenges with some administration methods. The use of the suprachoroidal space (SCS), which is the region between the sclera and the choroid, is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure. Preclinical data on agents such as vascular endothelial growth factor inhibitors and triamcinolone acetonide (TA) indicate that administration via suprachoroidal injection results in more posterior distribution of the pharmacologic agent, with higher exposure to the sclera, choroid, retinal pigment epithelium cells and retina, and lesser exposure to the anterior segment, than observed with IVT administration. Based in part on these findings, clinical trials have explored the efficacy and safety of suprachoroidal administration of pharmacologic therapies in conditions affecting the posterior segment. Data on a proprietary formulation of TA administered by suprachoroidal injection show improvement in anatomic and visual outcomes in subjects with noninfectious uveitis, with the potential to mitigate the known risks of cataract and increased intraocular pressure (IOP) associated with the use of intraocular corticosteroids. Suprachoroidal administration appears to be a promising treatment modality and is also in the early stages of investigation for other possible applications, such as injection of antiglaucoma agents into the anterior SCS for long-lasting control of elevated IOP, and as a mode of delivery for gene- or cell-based therapies for retinal disorders.

Original languageEnglish (US)
Pages (from-to)460-472
Number of pages13
JournalActa Ophthalmologica
Issue number5
StatePublished - Aug 2019


  • choroid
  • macular edema
  • macular oedema
  • pharmacotherapy
  • retina
  • retinal vein occlusion
  • suprachoroidal
  • triamcinolone acetonide
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach'. Together they form a unique fingerprint.

Cite this